Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma

Rhein, Christine von; Scholz, Tatjana; Henß, Lisa; Kronstein‐Wiedemann, Romy; Schwarz, Tatjana; Rodionov, Roman N.; Corman, Victor M.; Tonn, Torsten; Schnierle, Barbara S.

doi:10.1016/j.jviromet.2020.114031

Cited by 87 publications

(90 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Twelve of 43 SARS-CoV-2-positive individuals presenting no or weak neutralizing titers agrees with a study of COVID-19 recovered patients (33).…”

Section: Seroneutralization Assaysupporting

confidence: 83%

“…A recent work reported that standard commercially available SARS-CoV-2 IgG results could be a useful surrogate for neutralizing antibody testing (32). However, in the present study, antibody neutralizing titers were determined in vitro by using a native SARS-CoV-2 strain to be closer to the physiological infection of cells by SARS-CoV-2 in northeast France (33). Twelve of 43 SARS-CoV-2–positive individuals presenting no or weak neutralizing titers agrees with a study of COVID-19 recovered patients (33).…”

Section: Discussionmentioning

confidence: 97%

“…Second, seroprevalent cases were carefully identified by using several methods for confirming seropositivity (figure 1). Third, seroneutralization capacity was investigated in duplicate, in line with recommended standard practices, instead of derived from IgG results (33,34) The study has some limitations. First, the sampling electoral database, chosen for its immediate availability in such a small and delimited area, did not completely cover the adult population because some people left the area (among the 6094 people invited, 38% were not really solicited [wrong addresses, death etc.…”

Section: Seroneutralization Assaymentioning

confidence: 99%

See 2 more Smart Citations

Seroprevalence of SARS-CoV-2, symptom profiles and seroneutralization during the first COVID-19 wave in a suburban area, France

Gégout-Petit

Jeulin

Legrand

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: The World Health Organisation recommends monitoring the circulation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to estimate anti–SARS-CoV-2 total immunoglobulin (IgT) antibody seroprevalence and describe symptom profiles and in vitro seroneutralization in Nancy, France, in spring 2020. Methods: Individuals were randomly sampled from electoral lists and invited with household members over 5 years old to be tested for anti–SARS-CoV-2 (IgT, i.e. IgA/IgG/IgM) antibodies by ELISA (Bio-rad). Serum samples were classified according to seroneutralization activity >50% (NT50) on Vero CCL-81 cells. Age- and sex-adjusted seroprevalence was estimated. Subgroups were compared by chi-square or Fisher exact test and logistic regression. Results. Among 2006 individuals, 43 were SARS-CoV-2–positive; the raw seroprevalence was 2.1% (95% confidence interval 1.5 to 2.9), with adjusted metropolitan and national standardized seroprevalence 2.5% (1.8 to 3.3) and 2.3% (1.7 to 3.1). Seroprevalence was highest for 20- to 34-year-old participants (4.7% [2.3 to 8.4]), within than out of socially deprived area (2.5% vs 1%, P=0.02) and with than without intra-family infection (p<10-6). Moreover, 25% (23 to 27) of participants presented at least one COVID-19 symptom associated with SARS-CoV-2 positivity (p<10-13), with anosmia or ageusia highly discriminant (odds ratio 27.8 [13.9 to 54.5]), associated with dyspnea and fever. Among the SARS-CoV-2-positives, 16.3% (6.8 to 30.7) were asymptomatic. For 31 of these individuals, positive seroneutralization was demonstrated in vitro. Conclusions: In this population of very low anti-SARS-CoV-2 antibody seroprevalence, a beneficial effect of the lockdown can be assumed, with frequent SARS-CoV-2 seroneutralization among IgT-positive patients. Clinical Trial Registration ID #: NCT04448769

show abstract

“…Twelve of 43 SARS-CoV-2-positive individuals presenting no or weak neutralizing titers agrees with a study of COVID-19 recovered patients (33).…”

Section: Seroneutralization Assaysupporting

confidence: 83%

Section: Discussionmentioning

confidence: 97%

Section: Seroneutralization Assaymentioning

confidence: 99%

See 1 more Smart Citation

Seroprevalence of SARS-CoV-2, symptom profiles and seroneutralization during the first COVID-19 wave in a suburban area, France

Gégout-Petit

Jeulin

Legrand

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…When using the manufacturer’s cut-off for a positive result (≥20%), we find in all 3 groups that more than 90% of donors show a positive result. If the cut-off according to Rein et al [ 18 ] is adjusted, it can be seen that in group 1 only 30%, in group 2 78% and in group 3 still 96% of the donors are positive ( S4 Fig ). Based on this result, a correlation was calculated which showed a rho of 0.720 and a p.value of <0.001.…”

Section: Resultsmentioning

confidence: 99%

Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19

et al. 2021

View full text Add to dashboard Cite

Background The novel coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread across the world. The aim of our study was to characterize mild courses and to determine the antibody status for these patients. Methods We initiated an appeal for convalescent plasma donations. 615 people contacted us, and we ultimately included 426 in our analyses, in whom it was possible to assume COVID-19 based on detection of specific SARS-CoV-2 antibodies or virus detection during the disease using RT-PCR. Results The median duration of the disease was 12 days and the most common symptoms were fatigue, cough and olfactory and gustatory dysfunction. Anti-SARS-CoV-2 IgG was detected in 82.4% of the persons and IgA antibodies were found in 73.9%. In 10.8%, no antibodies were detectable despite a positive RT-PCR result during the disease. Nevertheless, of 24 persons with asymptomatic courses of COVID-19, antibodies against SARS-CoV-2 could be detected in 23 (96%). Furthermore, there was a correlation between the duration of the disease and the detection of IgG antibodies. In addition, a correlation between the determined IgG antibodies and neutralizing antibodies was shown. Conclusion In this study, we were able to describe mild COVID-19 courses and determine antibody statuses for them. It could be shown that, despite SARS-CoV-2 detection during the disease, not all individuals developed antibodies or their level of antibodies had dropped below the detection limit shortly after the end of the disease. The extent to which immunity to re-infection is given in persons with undetectable antibodies (IgG, IgA) needs to be investigated in future studies.

show abstract

“…Mazzini et al [ 153 ] observed that the RBD-based ELISA was efficient for quantifying IgA, IgM and IgG neutralizing antibodies against SARS-CoV-2. However, the study by von Rhein et al [ 154 ] showed that although the ELISA is capable of quantifying neutralizing antibodies, its performance was lower when compared to the plate reduction neutralization test (PRNT) and a lentiviral vector based pseudotype neutralization assay. The low performance of this assay in this context may be related to its ability to detect only neutralizing antibodies that block the interaction between the RBD region and the receptor-angiotensin converting enzyme II (ACE2) and, even though most neutralizing antibodies have this action, other types of neutralization mechanisms have been described [ 155 ].…”

Section: Serological Testsmentioning

confidence: 99%

The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature

Machado

Hodel

Barbosa-Júnior

et al. 2020

Viruses

View full text Add to dashboard Cite

Diagnostic tests have been considered as the main alternative for the control of coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as a correct diagnosis allows for decision making when facing the disease, particularly as there is a lack of effective therapeutic protocols and vaccines. Thus, in this review, we summarized the main diagnostic approaches currently available for the diagnosis of SARS-CoV-2 infection in humans based on studies available in article databases. The tests can be organized into two main categories: nucleic acid-based tests, recommended for the initial detection of the virus, and serological tests, recommended for assessing the disease progression. The studies have shown that the performance of diagnostic methods depends on different factors, such as the type of samples and the characteristics of each assay. It was identified that the positivity of the tests is mainly related to the onset of symptoms. We also observed that point-of-care diagnoses are considered as one of the main trends in this area, due to the low-cost and simplicity of the assay; however, the analytical performance must be critically analyzed. Thus, the COVID-19 pandemic has highlighted the critical role of diagnostic technologies in the control of infectious diseases.

show abstract

Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma

Cited by 87 publications

References 24 publications

Seroprevalence of SARS-CoV-2, symptom profiles and seroneutralization during the first COVID-19 wave in a suburban area, France

Seroprevalence of SARS-CoV-2, symptom profiles and seroneutralization during the first COVID-19 wave in a suburban area, France

Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19

The Main Molecular and Serological Methods for Diagnosing COVID-19: An Overview Based on the Literature

Contact Info

Product

Resources

About